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Abstract 
In contrast to patent foramen ovale, that is highly prevalent in the general population, atrial 
septal defect (ASD) is a rare congenital heart defect. The effect of ASD closure on headache 
and migraine remains a matter of controversy. The objectives of the study were (i) to 
determine headache prevalence in consecutive patients with ASD scheduled for percutaneous 
closure for cardiologic indications, using the classification of the International Headache 
Society and (ii) to compare headache characteristics before and after closure of ASD. In this 
observational case series no a priori power analysis was performed. Twenty-five consecutive 
patients were prospectively included over 27 months. Median duration of follow-up was 12 
months, [Interquartile range 0]. Prevalence of active headache seemed to be increased 
compared to the general population: Any headaches 88% (95% confidence interval 70-96), 
migraine without aura 28% (14-48), migraine with aura 16% (6-35). After ASD closure, we 
observed a slightly lower headache frequency (median frequency 1.0 [2.6] vs. 0.3 [1.5] 
headaches per month; p=0.067). In patients with ongoing headaches, a significant decrease in 
headache intensity (median VAS 7 [3] vs. 5 [4]; p=0.036) was reported. Three patients with 
migraine with aura before the intervention reported no migraine with aura attacks at follow-
up, two of them reported ongoing tension-type headache, one migraine without aura. In 
summary, this prospective observational study confirms the high prevalence of headache, 
particularly migraine, in ASD patients and suggests a possible small beneficial effect of ASD 
closure. 
 
 
 
 
 
 
 
 
 
 
Abbreviations: ASD…atrial septal defect, MwA…migraine with aura, MwoA…migraine 
without Aura, p…probable, ETTH…episodic tension-type headache, 
CTTH…chronic tension-type headache. 
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Introduction 
In recent years an increased prevalence of cardiac shunts in patients with migraine with aura 
(MwA) has been reported (1-2). There is evidence, mostly from retrospective case series, that 
migraine can substantially improve or disappear after closure of a patent foramen ovale (PFO) 
or an atrial septal defect (ASD)(3-4). In those studies, migraine was a comorbid condition and 
not the cause for shunt closure. Of note, the only prospective, randomised, sham-controlled 
trial to assess the effect of PFO closure on MwA was negative (5). The present study was 
motivated by the observation that ASD closure can exacerbate migraine auras (6-7) . To date 
the influence of ASD closure on migraine is not clear. Case series reporting exacerbation or 
new appearance of MwA after this intervention contrast with studies reporting improvement 
(3, 8) . The objectives of the study were (i) to determine headache prevalence in consecutive 
patients with ASD using the classification of the International Headache Society (9)  and (ii) 
to compare headache characteristics before and after closure of ASD in a prospective study. 
 
Methods 
The study was approved by the ethics committee of the Medical University of Vienna. From 
January 2006 until March 2008, unselected patients with secundum ASD, who were 
scheduled for interventional closure for cardiologic indications at the Department of 
Cardiology, Medical University of Vienna, were investigated by a neurologist (FR) on the day 
before the intervention after informed consent. Headache diagnoses were made based on the 
classification of the International Headache Society (ICH-D II) (9). Frequency, duration and 
intensity of headaches were recorded, as well as frequency of auras. Intensity was measured 
using the visual analogue scale (VAS) from 0-10 cm. All patients underwent catheter closure 
with an Amplatzer septal occluder device guided by transesophageal echocardiography. 
Transthoracal echocardiography was performed one day, 8 days, and 3 months after the 
procedure. 100 mg ASS / day for 6 months was started as a routine prophylaxis one day 
before the intervention. Some patients remained on phenprocoumon, or clopidogrel, 
depending on comorbidities (Table 1). All patients were followed-up by the same neurologist 
one week and 12 [Interquartile range 0] months after the intervention by telephone-interview.  
Statistics:  
As this was an observational study, no a priori power analysis was performed. Headaches 
prevalences given in per cent with 95% CI (Wilson) were compared to literature data from 
Austria (10), where available (all headaches, MwoA, MwA), or global prevalence data 
(tension-type headache)(11). Because there were more women than men (16:9) in our patient 
sample, increased headache prevalence compared to the general population with 
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approximately equal numbers of women and men might be observed. Therefore, prevalence 
data from the literature adjusted for gender distribution in our sample were also provided: 
  
Adjusted prevalence = [16 x (prevalence in females) + 9 x (prevalence in males)] / 25. 
 
Frequency, duration, and intensity of all headaches and migraine, as well as frequency of 
auras were compared before and 12 months after the intervention.  Assuming that data are not 
normally distributed, values are presented as median and interquartile range [IQR]. The non 
parametric paired Wilcoxon signed-rank test was used to compare variables before and after 
the intervention. All p<0.05, two-tailed, were considered significant. Headache frequency was 
considered the main outcome parameter. For headache duration and intensity, only patients 
with ongoing headaches at follow-up were considered. In case of significant differences, the 
median decrease or increase was calculated to provide a measure of effect size. SPSS for 
Windows, Version 12.0, was used for calculations. Correction for multiple comparisons was 
not performed. 
 
Results 
Headache prevalence 
An outline of case histories with demographic and clinical data is presented in Table 1. 
Twenty-five patients (16 women; median age 50 [25] years) were included into the study. In 
two patients, ASD was not closed (one patient refused intervention and in one the defect was 
found to be too large for closure at balloon stretched diameter measurement), one patient was 
lost during follow-up after 3 months (P11, no change in infrequent episodic tension-type 
headache (TTH) until then). These three patients were excluded from longitudinal analyses. 
None of the patients reported complications, in none of them residual shunt was found in 
echocardiographic controls.  
Prevalence for any headaches (88%; 95% CI 70-96), MwoA (28%; 14-48), and MwA (16%; 
6-35) seemed to be higher compared to literature data from the general population (Table 2). 
Prevalence for tension-type headache (40%; 23-59) was comparable to the general population.  
 
Headache frequency, duration, and intensity 
Results for these parameters are summarized in Table 3. Considering all patients, median 
headache frequency decreased from 1.0 [2.6] headaches per month before the intervention to 
0.3 [1.5] headaches per month after the intervention (p=0.067; Fig. 1). Considering only 
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migraine, median monthly attack frequency was 1.5 [3.9] before and 0.33 [0.9] after the 
intervention (n.s.; Fig. 2). Headache duration was not significantly changed before and after 
the intervention. Considering all patients with ongoing headaches, pain intensity was 
significantly lower after the intervention (median VAS 7 [3] before vs. 5 [4] after; p=0.036). 
The median reduction in VAS was 0.25 [2.75]. Considering only patients with ongoing 
migraine attacks, headache intensity was unchanged (Table 3).  
 
Observations in single patients with migraine 
In 3 migraine with aura (MwA) patients, no auras were reported 6 months after the 
intervention (follow up 20 months), in one MwA patient, attack frequency decreased 
markedly, in one patient with probable MwA, attack frequency remained unchanged (Fig 3). 
In the 3 patients in who reported no auras at follow-up, episodic tension-type headache 
(ETTH) (P15, P22) or MwoA (P24) persisted at low frequencies.  One patient with MwoA 
and ETTH (P8) reported no migraine attack after the intervention, but ETTH persisted (Table 
1). 
An increased attack frequency of MwoA was observed in 3 patients 3 months after ASD 
closure (P13, P16, P17). Attack frequency decreased to baseline or below at 6 months in these 
patients. A single prolonged aura during a migraine attack was observed in one patient (P24) 
about three months after ASD closure. 
 
 
Discussion 
In contrast to PFO that is highly prevalent in the general population, ASD is a rare condition 
that affects only 1-3 per 10 000 births (12). The prevalence of headache, particularly 
migraine, in consecutive patients with ASD seemed to be increased compared to the general 
population, which is in accordance with previous studies reporting prevalences of 11-22% for 
MwA and 12-19% for migraine without aura (MwoA) (3, 8, 13) in this patient group. Large 
confidence intervals in our sample represent uncertainty in the given sample size. To the best 
of our knowledge it is currently not clear, whether the prevalence of ASD is elevated among 
patients with migraine.  The prevalence of right-to-left shunts –most frequently related to a 
PFO- was found elevated in MwA (1-2), although this has been challenged recently (14). 
Nevertheless it is believed that microemboli can evoke cortical spreading depression which 
probably underlies migraine aura in a subgroup of patients (14). This could explain an 
association between MwA and cardiac shunts. Alternatively, inheritance of common genetic 
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factors for cardiac defects and migraine with aura has been suggested. Common inheritance of  
atrial shunts including ASD with migraine with aura was observed in some families (15).  
Considering all types of headache, a slightly lower attack frequency after ASD closure was 
observed, although this was not significant, possibly because of the small sample size.  Taking 
into account all headache types in patients with ongoing headaches, intensity was significantly 
lower after ASD closure. A statistically significant change in the VAS does not imply a 
meaningful reduction in pain for most of patients. The median reduction in VAS was only 
0.25. 
Three patients with MwA before the intervention reported no auras at follow-up. However, 
other headaches (ETTH or MwoA) persisted at low frequencies. In addition, two of these 
patients had only rare auras before the intervention, suggesting a declining natural course. 
These patients were on oral anticoagulation or antiplatelet therapy already before ASD 
closure so that an effect of medication can be considered unlikely. 
An increased attack frequency of MwoA was observed in 3 patients 3 months after ASD 
closure. Attack frequency decreased to baseline or below at 6 month in these patients. A 
single prolonged aura during a migraine attack was reported by one patient about three 
months after ASD closure, probably without any relation to the intervention. 
In none of the patients we observed an increase in headache attacks in the first week after the 
intervention; in none of them we observed de novo migraine. One patient, who was diagnosed 
probable chronic tension-type headache, suffering from daily headaches before the 
intervention, remained completely headache free thereafter. We suggest that this patient might 
have suffered from headache attributed to hypoxia, since an association between tension-type 
headache and cardiac shunts seems unlikely. 
Only a few studies systematically investigated the effect of ASD closure on migraine. In one 
prospective (8) and one retrospective (3) study, respectively, a significant decrease in 
migraine prevalence was found after ASD closure, particularly in MwA. However several 
shortcomings of these studies merit discussion. In the study of Luermans et al (8), migraine 
was assessed prospectively using questionnaires based on IHS diagnostic criteria in 68 
patients with ASD, albeit only 84% of patients returned questionnaires 12 months after the 
intervention. About half of those who did not return questionnaires were considered suffering 
from migraine before the intervention; therefore the question of response bias arises. The 
study of Azarbal and co-workers (3) was a retrospective evaluation of headache based on self-
report of patients on the basis of a diagnosis made by either their primary care physician or 
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their neurologist. It included 26 patients with ASD. Diagnostic headache criteria were not 
used.  
In another retrospective study using questionnaires no influence on migraine prevalence was 
noted at least 6 months after the intervention in 114 patients with ASD (13). In this study 
several patients developed de novo migraine that disappeared at long-term follow-up (16). An 
increased attack frequency or de novo development of migraine, mostly with aura, has been 
repeatedly reported (6, 17-19) in single cases or case series. Sharifi et al (19) reported 
response of these “post ASD closure headaches” to a loading dose of 300 mg clopidogrel 
followed by 75 mg/d clopidogrel for 6 months. In a retrospective analysis, Rodes-Cabau et al 
found de novo migraine in 12% of patients after closure of an ASD, who were migraine free 
before the intervention (17). In two thirds of these patients, migraine persisted 2 years after 
the intervention. 
 
Limitations of the present study are the sample size and the open design. A small beneficial 
effect of ASD closure is suggested. A placebo-effect can be considered unlikely, since ASDs 
were closed for cardiologic reasons and patients had no expectations concerning improvement 
of their headaches. After ASD closure most patients received platelet inhibitors until 6 months 
after the intervention, whereas clinical data were recorded 12 months thereafter. Three 
patients, who remained on platelet inhibitors or oral anticoagulation at follow-up, were on 
either platelet inhibitors or oral anticoagulants already before the intervention. Therefore, 
modifications of anticoagulant/antiplatelet therapy are unlikely to be a confounder.   
Strength of this series is that all patients were seen and prospectively followed up by a 
neurologist, making headache diagnoses based on the most recent IHS classification. All 
types of headaches were considered. 
 
In summary, this observational study confirms the high prevalence of headache, particularly 
migraine, in ASD patients. In addition, it suggests a small beneficial effect on headache in the 
long run, although a transient increase in attack frequency was observed in a few patients.  
We conclude that the relationship between ASD and migraine deserves further systematic 
investigation, for instance with case-control studies. 
 
 
.
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Patient Age/sex ICH D-II diagnoses Clinical comments 
P1 49/m MwoA, MOH ASD was not closed on the patient’s choice. He suffered from ischemic stroke after 10 months. 
P2 25/m - No headaches reported 
P3 
 
 
 
58/f MwoA Minor stroke several months before the intervention with right-sided hemihypesthesia and residual aphasia. 
Clopidogrel 75 mg/month. An MRI before ASD closure showed a small infarct in the left internal capsule and 
thalamus, an MRI on the day after ASD closure was unchanged.  She noted a decrease in headache frequency. 
Clopidogrel was continued. 
P4 
 
52/f MwoA This patient had been on phenprocumon several months before the intervention. She remained on it one year after the 
ASD closure. No change in headache frequency reported. 
P5 
 
49/m pMwoA Before closure he fulfilled diagnostic criteria for MwoA, except duration of 3.5 h. Headaches unchanged 14 months 
after ASD closure. 
P6 75/f Infrequent ETTH Suffers from headache only rarely, no change experienced 
P7 68/f Infrequent ETTH Phenprocuomon before intervention, phenprocumon + ASS after intervention for 6 months. No change reported  
P8 
 
 
51/f MwoA, ETTH This patient took ASS one month before intervention. She suffered from a typical migraine with aura attack one day 
after the intervention; since then no migraine headaches had occurred, but she suffered from episodic tension type 
headaches about twice/month (takes medication). 
P9 
 
70/f Infrequent ETTH Only rare headaches before and after the intervention (once every 4 months). No headaches after 6 months. (Follow-
up 12 months) 
P10 
 
25/f pMwoA Before intervention 1-2 headaches/months. Decrease after intervention. No headaches 12 months after the 
intervention. 
P11 29/m Infrequent ETTH No change after 3 months. Lost during follow-up. 
P12 39/f ETTH Initial headache frequency 1/month; remained unchanged after 3 and 6 months. At 12 months 3 headaches/month  
P13 
 
42/f MwoA Increase in attack frequency after 3 months to 4 headaches/months. After 6 months headache frequency similar to 
before the intervention with 1-2/month 
P14 59/f Infrequent ETTH ASD was not closed because the balloon stretched diameter was too large.  The patient refused surgery. 
P15 
 
 
 
 
66/f ETTH, MwA (typical aura without 
migraine headache) 
Since young adulthood typical MWA (several attacks/month). Nine years ago she suffered from minor stroke with 
left-sided hemiparesis, the diagnosis of ASD was made and she was set on phenprocomon.  She experienced a 
significant reduction of her auras, headaches disappeared, which the patient attributed to her retiring. The patient had 
Typical aura 5 months after the intervention; another one week later, no headache at both instances. Since then no 
auras.  
P16 
 
 
 
41/f MWA , MWOA after intervention  This patient was on ASS 100 mg/d and 1.25 mg/d bisoprolol before the intervention.  Clopidogrel was added after 
ASD closure, Nabivolol for hypertension. Three months after intervention frequent migraine without aura with use of 
caffeine + ergotamine, diagnostic criteria for MOH were not fulfilled. Six months after the intervention, attack 
frequency decreased below baseline (less than one headache/month). 
P17 
 
 
 
38/m pMwoA Minor stroke with aphasia and left-sided hemiparesis 8 months ago led to diagnosis of ASD. Oral anticoagulation with 
phenprocoumon was started. Three weeks after ASD closure almost daily holocranial pulsating headache worsened by 
movements without vegetative symptoms, which lasted until three months after the intervention. Six months after the 
intervention only rare headaches (once every three months). One year after the intervention the patient was still on 
Table 1:  Clinical features in 25 consecutive patients scheduled for ASD-closure for cardiologic indications. Abbreviations: MOH … medication 
overuse headache MwoA…migraine without aura, MwA… migraine with aura. p…probable, ETTH…episodic tension-type headache, 
CTTH…chronic tension-type headache. 
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 ASS 100 mg/d 
P18 40/f pMWA, pMwoA Recurrent headaches lasting for 2 weeks. Visual aura most of times. No change observed. 
P19 81/m - No headaches reported 
P20 42/f MwoA MwoA for five years. Relief of headaches after frovatriptan 2.5 mg. No change after ASD closure reported 
P21 77/f - No headaches reported 
P22 
 
 
58/f MWA, ETTH MWA since age of 35 and ETTH once / month. Typical visual aura (fortification spectra) 1-2/month with attack free 
periods up to three months. Headaches became less intense over time, but auras continued in the same frequency. 
ASD was diagnosed because of dyspnoea when walking upstairs. After ASD closure she received lisinopril 5 mg/d for 
hypertension. She suffered from visual auras associated with photophobia and nausea twice five 5 months after the 
intervention with an interval of one week. In general, she feels much better after the intervention and can easily walk 
upstairs. No more auras since then (Follow-up 20 months). ETTH unchanged 
P23 
 
 
35/f pCTTH Daily “pressure” behind left eye without accompanying symptoms, onset unclear. ASD was diagnosed because of 
dyspnoea. Complete relief of headache one week after the intervention (Follow-up 20 months). Feels much better in 
general. 
P24 
 
 
 
59/f MwoA 
MwA 
MwA and MwoA for several years, MwA frequency several times/year. Migraine attacks were sometimes associated 
with vertigo. ASD discovered during routine work-up. Before the intervention the patient was on ASS, clopidogrel, 
bisoprolol. Three months after ASD closure prolonged visual aura during migraine attack. Since then no auras 
(Follow-up 20 months).  MwoA less frequent, less intense 
P25 43/f ETTH ETTH for 5 years. No change experienced 
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Table 2 
Headache prevalence in 25 consecutive patients with ASD compared to literature data for the 
general population. *Adjusted for gender distribution, see text. 
 
 
Headache diagnosis Present study 
% (N) 
95% CI General population  
 
    %            % adj. 
Migraine with aura 16.0 (4) (6-35) 2.3 2.5* 
Migraine without aura 28.0 (7) (14-48) 5.6 6.1* 
Tension-type headache 40.0 (10) (23-59) 38.0 41.5* 
No headache diagnosis 12.0 (3) (4-30) 51.6 49.3* 
Probable migraine with 
aura 
4.0 (1) (1-25)   
Probable migraine without 
aura 
16.0 (4) (6-35)   
Probable chronic tension-
type 
4.0 (1) (1-25)   
 
 
 
 
 
Table 3 
Headache characteristics in 22 ASD patients before and after percutaneous ASD closure. For 
duration and frequency, only patients with ongoing headache attacks were considered. Values 
are presented as median (interquartile range in brackets). 
 
 
All Headaches Before After Wicoxon 
signed- rank 
test 
Frequency 
Headaches/month 
1.0 [2.6] 0.3 [1.5] p=0.067 
Duration 
h 
4.3 [9.5] 3.5 [9.6] n.s. 
Intensity 
VAS 
7 [3] 5 [4] p=0.036 
Migraine Before After  
Frequency 
Headaches/month 
1.5 [3.9] 0.33 [0.9] n.s. 
Duration 
h 
4.3 [15.6] 6.0 [47.5] n.s. 
Intensity 
VAS 
7.25 [1.9] 6.5 [2.6] n.s. 
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Figure 1: Headache frequency in consecutive patients with ASD before and after percutaneous ASD 
closure
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Figure 2: Attack frequency in consecutive atrial septal defect (ASD) patients with migraine with and without 
aura before and after percutaneous ASD closure
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Figure 3: Attack frequency in consecutive atrial septal defect (ASD) patients with migraine with aura and 
probable migraine with aura before and after percutaneous ASD closure
